---
figid: PMC3797434__srep02960-f7
figlink: /pmc/articles/PMC3797434/figure/f7/
number: F7
caption: Once LPS from Gram-negative bacteria is recognized by TLR4, the TLR4-MyD88
  pathway is triggered, and early-phase TNFα expression is initiated through the activation
  of NF-κB and MAPKs. Activation of PKCε results in activation of TRAM-TRIF, which
  is responsible for late-phase TNFα and type I interferon (i.e., IFN-α/β) expression.
  Concurrently, IL-32γ binds to PR3 and activates PAR2. PAR2-Ras and -TRIF pathways
  potentially induce TNFα expression, and the latter pathway in particular induces
  type I interferon expression via IRF3/7. At that time, TAG is synthesized to terminate
  TLR4-TRIF signaling, with TRIF preferentially recruited to PAR2 instead. Following
  LPS-induced TNFα expression mainly through TLR4, LPS-induced IL-32γ-PAR2 signaling
  gradually increases type I interferon expression, which potentially translates innate
  to adaptive immunity, or ceases a series of LPS-induced acute inflammation.
pmcid: PMC3797434
papertitle: IL-32-PAR2 axis is an innate immunity sensor providing alternative signaling
  for LPS-TRIF axis.
reftext: Masanori Nakayama, et al. Sci Rep. 2013;3:2960.
pmc_ranked_result_index: '42170'
pathway_score: 0.9492053
filename: srep02960-f7.jpg
figtitle: IL-32-PAR2 axis is an innate immunity sensor providing alternative signaling
  for LPS-TRIF axis
year: '2013'
organisms: Homo sapiens
ndex: 057b17e0-def8-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3797434__srep02960-f7.html
  '@type': Dataset
  description: Once LPS from Gram-negative bacteria is recognized by TLR4, the TLR4-MyD88
    pathway is triggered, and early-phase TNFα expression is initiated through the
    activation of NF-κB and MAPKs. Activation of PKCε results in activation of TRAM-TRIF,
    which is responsible for late-phase TNFα and type I interferon (i.e., IFN-α/β)
    expression. Concurrently, IL-32γ binds to PR3 and activates PAR2. PAR2-Ras and
    -TRIF pathways potentially induce TNFα expression, and the latter pathway in particular
    induces type I interferon expression via IRF3/7. At that time, TAG is synthesized
    to terminate TLR4-TRIF signaling, with TRIF preferentially recruited to PAR2 instead.
    Following LPS-induced TNFα expression mainly through TLR4, LPS-induced IL-32γ-PAR2
    signaling gradually increases type I interferon expression, which potentially
    translates innate to adaptive immunity, or ceases a series of LPS-induced acute
    inflammation.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAPK11
  - MAPK3
  - MAPK8
  - MAPK1
  - JUNB
  - RELB
  - IFNA14
  - IRF6
  - JUN
  - RELA
  - IRF3
  - PRTN3
  - FOSL2
  - MAPK10
  - IFNA13
  - MAPK14
  - FOSB
  - IRAK4
  - IFNA17
  - TRAF6
  - IRF7
  - REL
  - IL32
  - NFKB1
  - MAPK13
  - MAPK9
  - IFNA10
  - IFNA8
  - IFNA4
  - FOS
  - MAPK12
  - ARAF
  - TBK1
  - IFNA5
  - IFNA6
  - MYD88
  - IFNA16
  - BRAF
  - JUND
  - NFKB2
  - IFNA1
  - IFNA2
  - IFNA21
  - IFNA7
  - NRAS
  - RAF1
  - KRAS
  - FOSL1
  - HRAS
  - Cancer
genes:
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: AP-1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: JUNB
  entrez: '3726'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELB
  entrez: '5971'
- word: IFNa/B↑
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA14
  entrez: '3448'
- word: LPS
  symbol: LPS
  source: hgnc_prev_symbol
  hgnc_symbol: IRF6
  entrez: '3664'
- word: AP-1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: JUN
  entrez: '3725'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELA
  entrez: '5970'
- word: IRF3/7
  symbol: IRF3
  source: hgnc_symbol
  hgnc_symbol: IRF3
  entrez: '3661'
- word: PR3
  symbol: PR-3
  source: hgnc_alias_symbol
  hgnc_symbol: PRTN3
  entrez: '5657'
- word: AP-1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: FOSL2
  entrez: '2355'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: IFNa/B↑
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA13
  entrez: '3447'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: AP-1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: FOSB
  entrez: '2354'
- word: IRAK4
  symbol: IRAK4
  source: hgnc_symbol
  hgnc_symbol: IRAK4
  entrez: '51135'
- word: IFNa/B↑
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA17
  entrez: '3451'
- word: TRAF6
  symbol: TRAF6
  source: hgnc_symbol
  hgnc_symbol: TRAF6
  entrez: '7189'
- word: IRF3/7
  symbol: IRF7
  source: hgnc_symbol
  hgnc_symbol: IRF7
  entrez: '3665'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: REL
  entrez: '5966'
- word: IL-32
  symbol: IL32
  source: hgnc_symbol
  hgnc_symbol: IL32
  entrez: '9235'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: IFNa/B↑
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA10
  entrez: '3446'
- word: IFNa/B↑
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA8
  entrez: '3445'
- word: IFNa/B↑
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA4
  entrez: '3441'
- word: AP-1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: FOS
  entrez: '2353'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: TBK1
  symbol: TBK1
  source: hgnc_symbol
  hgnc_symbol: TBK1
  entrez: '29110'
- word: IFNa/B↑
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA5
  entrez: '3442'
- word: IFNa/B↑
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA6
  entrez: '3443'
- word: MYD88
  symbol: MYD88
  source: hgnc_symbol
  hgnc_symbol: MYD88
  entrez: '4615'
- word: IFNa/B↑
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA16
  entrez: '3449'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: AP-1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: JUND
  entrez: '3727'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB2
  entrez: '4791'
- word: IFNa/B↑
  symbol: IFN-alphaB
  source: hgnc_alias_symbol
  hgnc_symbol: IFNA8
  entrez: '3445'
- word: IFNa/B↑
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA1
  entrez: '3439'
- word: IFNa/B↑
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA2
  entrez: '3440'
- word: IFNa/B↑
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA21
  entrez: '3452'
- word: IFNa/B↑
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA7
  entrez: '3444'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: AP-1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: FOSL1
  entrez: '8061'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC3797434__F7
redirect_from: /figures/PMC3797434__F7
figtype: Figure
---
